Personal information

Activities

Collapse all

Employment (1)

University of Queensland Institute for Molecular Bioscience: Brisbane, QLD, AU

2015-07-01 to present
Employment
Source: Self-asserted source
Kai-Chen Wu

Education and qualifications (1)

University of Queensland: Brisbane, QLD, AU

2013-07-22 to 2015-07-22 | Master of Molecular Biology (Advanced)
Education
Source: Self-asserted source
Kai-Chen Wu

Works (13)

Ras-Related Protein Rab5a Regulates Complement C5a Receptor Trafficking, Chemotaxis, and Chemokine Secretion in Human Macrophages

Journal of Innate Immunity
2023 | Journal article
DOI: 10.1159/000530012
Contributors: Kai-Chen Wu; Nicholas D Condon; Timothy A. Hill; Robert C. Reid; David P. Fairlie; Junxian Lim
Source: check_circle
Crossref

Landscaping macrocyclic peptides: stapling hDM2-binding peptides for helicity, protein affinity, proteolytic stability and cell uptake

RSC Chemical Biology
2022 | Journal article
DOI: 10.1039/D1CB00231G
Contributors: Aline D. de Araujo; Junxian Lim; Kai-Chen Wu; Huy N. Hoang; Huy T. Nguyen; David P. Fairlie
Source: check_circle
Crossref

Synthesis of benzoxazole-based vorinostat analogs and their antiproliferative activity

Bioorganic Chemistry
2021-09 | Journal article
DOI: 10.1016/j.bioorg.2021.105132
Part of ISSN: 0045-2068
Source: Self-asserted source
Kai-Chen Wu

PAR2 induces ovarian cancer cell motility by merging three signalling pathways to transactivate EGFR

British Journal of Pharmacology
2021-02 | Journal article
DOI: 10.1111/bph.15332
Part of ISSN: 0007-1188
Part of ISSN: 1476-5381
Source: Self-asserted source
Kai-Chen Wu

HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates

Journal of Medicinal Chemistry
2021-02-25 | Journal article
DOI: 10.1021/acs.jmedchem.0c01967
Part of ISSN: 0022-2623
Part of ISSN: 1520-4804
Source: Self-asserted source
Kai-Chen Wu

Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class I HDAC Enzymes and Cancer Cell Proliferation

Journal of Medicinal Chemistry
2020-06-11 | Journal article
DOI: 10.1021/acs.jmedchem.0c00230
Part of ISSN: 0022-2623
Part of ISSN: 1520-4804
Source: Self-asserted source
Kai-Chen Wu

Potent Thiophene Antagonists of Human Complement C3a Receptor with Anti-Inflammatory Activity

Journal of Medicinal Chemistry
2020-01-23 | Journal article
DOI: 10.1021/acs.jmedchem.9b00927
Part of ISSN: 0022-2623
Part of ISSN: 1520-4804
Source: Self-asserted source
Kai-Chen Wu

Bicyclic Helical Peptides as Dual Inhibitors Selective for Bcl2A1 and Mcl-1 Proteins

Journal of Medicinal Chemistry
2018-04-12 | Journal article
DOI: 10.1021/acs.jmedchem.8b00010
Part of ISSN: 0022-2623
Part of ISSN: 1520-4804
Source: Self-asserted source
Kai-Chen Wu

A Potent Antagonist of Protease-Activated Receptor 2 That Inhibits Multiple Signaling Functions in Human Cancer Cells

Journal of Pharmacology and Experimental Therapeutics
2018-02 | Journal article
DOI: 10.1124/jpet.117.245027
Part of ISSN: 0022-3565
Part of ISSN: 1521-0103
Source: Self-asserted source
Kai-Chen Wu

Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a

Nature Communications
2017-12 | Journal article
DOI: 10.1038/s41467-017-00414-w
Part of ISSN: 2041-1723
Source: Self-asserted source
Kai-Chen Wu

Europium-Labeled Synthetic C3a Protein as a Novel Fluorescent Probe for Human Complement C3a Receptor

Bioconjugate Chemistry
2017-06-21 | Journal article
DOI: 10.1021/acs.bioconjchem.7b00132
Part of ISSN: 1043-1802
Part of ISSN: 1520-4812
Source: Self-asserted source
Kai-Chen Wu

Biased Signaling by Agonists of Protease Activated Receptor 2

ACS Chemical Biology
2017-05-19 | Journal article
DOI: 10.1021/acschembio.6b01088
Part of ISSN: 1554-8929
Part of ISSN: 1554-8937
Source: Self-asserted source
Kai-Chen Wu

Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2

Journal of Chemical Information and Modeling
2015-10-26 | Journal article
DOI: 10.1021/acs.jcim.5b00500
Part of ISSN: 1549-9596
Part of ISSN: 1549-960X
Source: Self-asserted source
Kai-Chen Wu
How many people are using ORCID?